Sep 3, 2020   SOURCE: BusinessWire

Low Affinity Sodium Glucose Cotransporter (SGLT2) Inhibitor - 2020 Pipeline Insight - ResearchAndMarkets.com

The "Low Affinity Sodium Glucose Cotransporter (SGLT2) Inhibitor - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

This report outlays comprehensive insights of present scenario and growth prospects across the mechanism of action. A detailed picture of the Low Affinity Sodium Glucose Cotransporter (SGLT2) Inhibitor pipeline landscape is provided, which includes the topic overview and Low Affinity Sodium Glucose Cotransporter (SGLT2) Inhibitor mechanism of action.

The assessment part of the report embraces, in-depth Low Affinity Sodium Glucose Cotransporter (SGLT2) Inhibitor commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes the product description, mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

Report Highlights

  • In the coming years, the Low Affinity Sodium Glucose Cotransporter (SGLT2) Inhibitor market is set to change due to the extensive research in this filed, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Low Affinity Sodium Glucose Cotransporter (SGLT2) Inhibitor R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • There are several companies involved in developing therapies for Low Affinity Sodium Glucose Cotransporter (SGLT2) Inhibitor . Launch of emerging therapies of Low Affinity Sodium Glucose Cotransporter (SGLT2) Inhibitor will significantly impact the market.
  • A better understanding of the target mechanism will also contribute to the development of novel therapeutics for Low Affinity Sodium Glucose Cotransporter (SGLT2) Inhibitor.
  • Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Low Affinity Sodium Glucose Cotransporter (SGLT2) Inhibitor ) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Key Questions Answered

  • What are the current treatment options available based on the Low Affinity Sodium Glucose Cotransporter (SGLT2) Inhibitor?
  • How many companies are developing therapies by working on Low Affinity Sodium Glucose Cotransporter (SGLT2) Inhibitor?
  • What are the principal therapies developed by these companies in the industry?
  • How many therapies are developed by each company for Low Affinity Sodium Glucose Cotransporter (SGLT2) Inhibitor to treat disease condition?
  • How many emerging therapies are in early-stage, mid-stage, and late stage of development for Low Affinity Sodium Glucose Cotransporter (SGLT2) Inhibitor?
  • Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other treatments?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Low Affinity Sodium Glucose Cotransporter (SGLT2) Inhibitor therapies?
  • Which are the dormant and discontinued products and the reasons for the same?
  • What is the unmet need for current therapies developed based on this mechanism of action?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Low Affinity Sodium Glucose Cotransporter (SGLT2) Inhibitor and their status?
  • What are the results of the clinical studies and their safety and efficacy?
  • What are the key designations that have been granted for the emerging therapies for Low Affinity Sodium Glucose Cotransporter (SGLT2) Inhibitor?
  • How many patents are granted and pending for the emerging therapies of Low Affinity Sodium Glucose Cotransporter (SGLT2) Inhibitor?

Key Topics Covered:

1. Report Introduction

2. Low Affinity Sodium Glucose Cotransporter (SGLT2) Inhibitor

3. Low Affinity Sodium Glucose Cotransporter (SGLT2) Inhibitor - Analytical Perspective

3.1. In-depth Commercial Assessment

3.1.1. Low Affinity Sodium Glucose Cotransporter (SGLT2) Inhibitor companies collaborations, Licensing, Acquisition Deal Value Trends

3.1.1.1. Assessment Summary

3.1.2. Low Affinity Sodium Glucose Cotransporter (SGLT2) Inhibitor Collaboration Deals

3.1.2.1. Company-Company Collaborations (Licensing/Partnering) Analysis

3.1.2.2. Company-University Collaborations (Licensing/Partnering) Analysis

3.1.2.3. Low Affinity Sodium Glucose Cotransporter (SGLT2) Inhibitor Acquisition Analysis

4. Therapeutic Assessment

4.1. Clinical Assessment of Pipeline Drugs

4.1.1. Assessment by Phase of Development

4.1.2. Assessment by Product Type (Mono/Combination)

4.1.2.1. Assessment by Stage and Product Type

4.1.3. Assessment by Route of Administration

4.1.3.1. Assessment by Stage and Route of Administration

4.1.4. Assessment by Molecule Type

4.1.4.1. Assessment by Stage and Molecule Type

4.1.5. Assessment by MOA

4.1.5.1. Assessment by Stage and MOA

4.1.6. Assessment by Target

4.1.6.1. Assessment by Stage and Target

5. Late Stage Products (Phase-III)

6. Mid Stage Products (Phase-II)

7. Early Stage Products (Phase-I)

8. Pre-clinical Products and Discovery Stage Products

9. Inactive Products

10. Dormant Products

11. Discontinued Products

12. Low Affinity Sodium Glucose Cotransporter (SGLT2) Inhibitor Product Profiles

13. Low Affinity Sodium Glucose Cotransporter (SGLT2) Inhibitor Key Companies

14. Low Affinity Sodium Glucose Cotransporter (SGLT2) Inhibitor Key Products

15. Dormant and Discontinued Products

15.1. Dormant Products

15.1.1. Reasons for being dormant

15.2. Discontinued Products

15.2.1. Reasons for the discontinuation

16. Low Affinity Sodium Glucose Cotransporter (SGLT2) Inhibitor - Unmet Needs

17. Low Affinity Sodium Glucose Cotransporter (SGLT2) Inhibitor - Future Perspectives

18. Low Affinity Sodium Glucose Cotransporter (SGLT2) Inhibitor Analyst Review

19. Appendix

20. Report Methodology

Companies Mentioned

  • Theracos
  • Jiangsu Hengrui Medicine Co.
  • Lexicon Pharmaceuticals
  • Sanofi
  • Avolynt
  • BHV Pharma
  • Chugai Pharmaceutical
  • Sirona Biochem
  • HEC Pharm
  • Sihuan Pharmaceutical Holdings Group
  • Johnson & Johnson
  • Mitsubishi Tanabe Pharma Corporation

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/s8lrbu